Metadata record for the manuscript "Real-world outcomes of venetoclax plus azacitidine versus 3+7 induction in newly diagnosed acute myeloid leukemia"

Abstract

This record describes the dataset generated and analysed in the study "Real-world outcomes of venetoclax plus azacitidine versus 3+7 induction in newly diagnosed acute myeloid leukemia" (BMC Cancer; submission ID 64a31579). Study. A single-centre retrospective cohort of 311 adults with newly diagnosed acute myeloid leukemia treated at the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China, between May 2018 and August 2025. Patients received venetoclax plus azacitidine or standard 3+7 induction. The study was approved by the Institutional Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (approval No. K202506-30); written informed consent was waived because of the retrospective, non-interventional design. Dataset. The dataset comprises (i) variant-level data for each patient as reported by a targeted 74-gene next-generation sequencing panel (gene, variant, and, where reported, variant allele frequency), and (ii) linked de-identified clinical and outcome annotations (age, sex, ECOG performance status, AML type, blood counts, blast percentage, ELN 2022 risk, treatment regimen, response, measurable residual disease, allogeneic transplantation, overall survival and relapse-free survival). Records are identified only by sequential pseudonymous codes (P001-P311); the key linking these codes to identifiable records is held by the study team under the ethics approval. No direct identifiers are included. Source of the molecular data. The 74-gene panel was not performed by the investigators and was not performed for research purposes. It was ordered as part of routine clinical care for diagnosis and risk stratification and was performed on clinical samples by a certified third-party clinical laboratory. The investigators retrieved the clinical sequencing reports retrospectively from the medical records and used the variants reported in those reports. The raw sequence files (FASTQ/BAM) are generated and retained by the third-party laboratory that performed the testing and were never transferred to the investigators. Access. The raw sequence files cannot be released. They are generated and retained by the third-party laboratory that performed the testing, they were never transferred to the investigators, and the investigators do not hold the rights to release them. The ethics approval for this study covers the retrospective use of the de-identified clinical records and reports. Depositing human genomic data from China in a repository outside China would additionally be subject to national requirements for the cross-border sharing of human genetic resources. No data files are attached to this metadata record. De-identified data supporting the findings of the study are available from the corresponding authors on reasonable request and subject to approval under the ethics approval stated above. Ethics approval: Institutional Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University, approval No. K202506-30. Funding: Xinjiang Uygur Autonomous Region Youth Science and Technology Top Talent Project - Youth Science and Technology Innovation Talent Training (No. 2022TSYCCX0027); Xinjiang Uygur Autonomous Region Distinguished Young Scientists Fund Project (No. 2022D01E72). Contact: Jie Wang (JieW629@163.com)